Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Novartis”

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of TherapiesActive Not Recruiting
NCT05885555Phase 2Updated Apr 13, 2026
Sponsor: Novartis Pharmaceuticals
Primary Immune Thrombocytopenia (ITP)
United States, Argentina, Australia, China, France +8 more
Managed Access Programs for LEE011, RibociclibAvailable
NCT05038631N/AUpdated Apr 13, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer
PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic CancerTerminated
NCT05518110Phase 2Updated Apr 13, 2026
Sponsor: Cancer Trials Ireland
Pancreatic Cancer
Ireland
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 MutationsActive Not Recruiting
NCT02381886Phase 1Updated Apr 13, 2026
Sponsor: Novartis Pharmaceuticals
Advanced Malignancies That Harbor IDHR132 Mutations
United States, Australia, Belgium, Canada, Germany +3 more
Primary Hyperparathyroidism and Gut MicrobiotaTerminated
NCT04948671N/AUpdated Apr 13, 2026
Sponsor: Centre Hospitalier Universitaire Vaudois
Hyperparathyroidism, Primary
Switzerland
A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 InhibitorsCompleted
NCT07512063N/AUpdated Apr 13, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer
United States
ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS PatientsActive Not Recruiting
NCT06345157N/AUpdated Apr 13, 2026
Sponsor: Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
Italy
Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure)Recruiting
NCT06659393N/AUpdated Apr 13, 2026
Sponsor: Novartis Pharmaceuticals
Pediatric Chronic Heart Failure
Japan
Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.Completed
NCT05959304Phase 4Updated Apr 13, 2026
Sponsor: Novartis Pharmaceuticals
Diabetic Macular Edema
India
Ribociclib for HR-positive HER2-negative Metastatic Breast CancerRecruiting
NCT07164976Phase 1, Phase 2Updated Apr 13, 2026
Sponsor: Nagoya City University
Breast Cancer
Japan
Eltrombopag With Standard Immunosuppression for Severe Aplastic AnemiaActive Not Recruiting
NCT01623167Phase 1, Phase 2Updated Apr 13, 2026
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Severe Aplastic Anemia
United States
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)Completed
NCT06097663Phase 2Updated Apr 9, 2026
Sponsor: Novartis Pharmaceuticals
Coronary Heart Disease · Clonal Hematopoiesis of Indeterminate Potential (CHIP)
United States, Canada, Germany
To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum MalariaCompleted
NCT04675931Phase 2Updated Apr 9, 2026
Sponsor: Novartis Pharmaceuticals
Severe Malaria
Burkina Faso, Côte d’Ivoire, Democratic Republic of the Congo, Kenya, Mozambique +2 more
Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial SpondyloarthritisCompleted
NCT04732117Phase 3Updated Apr 9, 2026
Sponsor: Novartis Pharmaceuticals
Non-radiographic Axial Spondyloarthritis
China
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to OfatumumabCompleted
NCT04353492Phase 3Updated Apr 9, 2026
Sponsor: Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
United States, Argentina, Australia, Austria, Belgium +22 more
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRPCompleted
NCT06031844Phase 2Updated Apr 9, 2026
Sponsor: Novartis Pharmaceuticals
Coronary Heart Disease
United States, Canada
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate CancerActive Not Recruiting
NCT06303713Phase 1Updated Apr 8, 2026
Sponsor: Dana-Farber Cancer Institute
Prostate Cancer · Metastatic Prostate Cancer · Metastatic Castration-resistant Prostate Cancer
United States
Simulect Versus ATG in Sensitized Renal Transplant PatientCompleted
NCT02377193Phase 4Updated Apr 8, 2026
Sponsor: University Hospital, Toulouse
Renal Transplant Rejection
France
LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to ChemotherapyCompleted
NCT02985125Phase 1, Phase 2Updated Apr 7, 2026
Sponsor: Georgetown University
Metastatic Pancreatic Adenocarcinoma
United States
Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.Completed
NCT05110196Phase 4Updated Apr 7, 2026
Sponsor: Novartis Pharmaceuticals
Non-Small Cell Lung Carcinoma
India
A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)Recruiting
NCT02819882N/AUpdated Apr 7, 2026
Sponsor: Spanish Breast Cancer Research Group
Breast Neoplasms
Spain
Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)Active Not Recruiting
NCT04980833Phase 2Updated Apr 2, 2026
Sponsor: Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum (PROS)
United States, France, Ireland, Spain
Impact of Implementation Strategies on Lp(a) Testing in Secondary Care SettingsRecruiting
NCT07508007N/AUpdated Apr 2, 2026
Sponsor: Novartis Pharmaceuticals
Implementing EAS/ESC Guideline Recommendation on Lp(a) Testing in Routine Practice
Germany
Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in ChinaRecruiting
NCT07476170N/AUpdated Apr 2, 2026
Sponsor: Novartis Pharmaceuticals
HR+/HER2- Advanced or Metastatic Breast Cancer
China
Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee OsteoarthritisTerminated
NCT04864392Phase 2Updated Apr 2, 2026
Sponsor: Novartis Pharmaceuticals
Osteoarthritis
United States, Argentina, Australia, Canada, China +10 more

Previous page Next page